Cell line · CVCL_0092
Papers99
1 to 20 of 99
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| ETV6 Rearrangement Suppresses CDKN1B Transcription by Disrupting an Intragenic Super-enhancer in Acute Lymphoblastic Leukemia. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. | Leukemia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Leukemia risk factor ARID5B coordinates HDAC-mediated transcriptional repression. | Nucleic Acids Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of CAR-T cell factors that contribute to myeloid cell activation. | Gene Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial ETF insufficiency drives neoplastic growth by selectively optimizing cancer bioenergetics. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual-antigen recognition iPSC-derived CAR-T cells for B-cell malignancies: establishment of a COVID-19 vaccine synergy strategy. | Front Cell Dev Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the Role of Environmental Factors on Chromosomal Translocations Associated With Childhood Leukaemia. | Cancer Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nucleotide-resolution mapping of regulatory elements via allelic readout of tiled base editing. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Distinguishing acute leukemia subtypes: The role of hsa_circ_0012152 and hsa_circ_0020093 in peripheral blood. | Oncol Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| GREM1 deficiency induced bone marrow adipose niche promotes B-cell acute lymphoblastic leukemia disease progression. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0092/papers